david drobne

New paper - Slovenian UR CARE Registry data suggest IBD is approached similarly in Academic and Non-academic settings - no need for the patients to travel long distances! journals.lww.com/eurojgh/fullte…

@GI_UMCLJ @MdpiMedicina This is one of the rare works exploring optimized iv vedolizumab (300mg q 4 weeks) switch to sc vedo - good new - no signal for loss of response

Congratulations to our IBD team. @daviddrobne et al. for the paper in @MdpiMedicina "Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease" mdpi.com/1648-9144/60/2…